Skip to main content

  • FDA: Paclitaxel Device Studies May Continue; Patients Should Be Informed of Late Mortality Signal; Will Work with Manufacturers to Change Labeling

    Clinical studies of paclitaxel-coated devices for use in the peripheral arteries may continue and should collect long-term safety – including mortality – and effectiveness data, the U.S. Food and Drug Administration said Wednesday.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details